Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T53684
(Former ID: TTDI01292)
|
|||||
Target Name |
Inflammation pathogenesis (IP)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Indeterminate colitis [ICD-11: DD72] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | HMPL-004 | Drug Info | Phase 3 | Inflammatory bowel disease | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Antagonist | [+] 1 Antagonist drugs | + | ||||
1 | HMPL-004 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of Hutchison Medi Pharma. | |||||
REF 2 | ClinicalTrials.gov (NCT01882764) A Phase III Maintenance Placebo Controlled Maintenance Trial Of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.